Ehrin Armstrong, MD
Interventional Cardiology · Englewood, CONPI 1699733634
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $491,667 of the $717,857 with a category attached, or 68.5%. 60 manufacturers reported payments, led by Philips North America LLC at 38.4% of the total. Reporting peaked in 2020 at $231,862 and has fallen 70.2% since, to $69,142 in 2025. Among interventional cardiology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 874 payments — averaging $821.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$275K
- Shockwave Medical, Inc$106K
- Cardiovascular Systems Inc.$55K
- Bard Peripheral Vascular, Inc.$52K
- Abbott$52K
- Boston Scientific$37K
- plus $140K from 54 others
Across 333 payments — averaging $5708.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$516K
- Bard Peripheral Vascular, Inc.$458K
- Shockwave Medical, Inc$354K
- Boston Scientific$181K
- Abbott$131K
- M.a. Med Alliance S.A.$63K
- plus $198K from 7 others
What the payments were for
- Consulting fees$491,66768%
- Speaking & faculty fees$164,23223%
- Travel & lodging$29,8214%
- Food & beverage$29,4214%
- Other$2,7150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Turbo Power$136,600
- IGT D Peripheral$63,200
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$56,759
- Vascular Lithotripsy$48,642
- Spectranetics Undiv$27,309
- Coronary Orbital Atherectomy System$19,631
- Peripheral Orbital Atherectomy System$19,414
- Tack Endovascular System$18,803
- GENERAL VASCULAR INTERVENTION$16,952
- IVUS Systems$15,700
- ESPRIT$13,753
- Product in Development$13,146
- Omnilink Elite vascular stent system$12,210
- Diamondback Peripheral$12,149
- IN.PACT Admiral$11,526
- SELUTION SLR PTA$10,063
- ELUVIA$9,470
- VIABAHN Endoprosthesis$9,375
- Endurant$7,787
- Perclose ProGlide suture mediated closure system$6,750
How this compares
$717,857 in reported general payments places this provider in the 95th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 47 | $47,494 |
| Repatha SureclickEvolocumab | 38 | $20,273 |
| XareltoRivaroxaban | 13 | $8,593 |
| JardianceEmpagliflozin | 11 | $7,555 |
| Amiodarone Hcl | 16 | $994 |
| ClopidogrelClopidogrel Bisulfate | 95 | $841 |
| Rosuvastatin Calcium | 27 | $281 |
| Alprazolam | 92 | $250 |
| Metoprolol Succinate | 23 | $217 |
| Carvedilol | 20 | $109 |
| Atorvastatin Calcium | 18 | $78 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 14 | $50 |
| Furosemide | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $3,497 | $8,59313 claims |
| Boehringer IngelheimJardiance | $35 | $7,55511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Englewood
- Yonatan Bitton-FaiwiszewskiEnglewood$36K
- Travis TagamiEnglewood$25K
- Regina LeeEnglewood$12K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.